PolarityTE Inc

PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. PolarityTE was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RegenETP, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm's products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. It was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.

PolarityTE, Inc. (PTE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

PolarityTE, Inc. (PTE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

SALT LAKE CITY , Dec. 27, 2022 /PRNewswire/ --  PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials (the "Company"), today announced that it signed a non-binding letter of intent (the "LOI") with Michael Brauser ("Brauser") for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash. As of December 23, 2022, there were 7,256,786 shares of the Company's common stock outstanding and unvested restricted stock units covering an additional 256,457 common shares.

PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company

SALT LAKE CITY , Nov. 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022. Recent Business and Financial Updates At the end of April 2022, PolarityTE began enrollment in its Phase III randomized controlled trial (RCT), which is a pivotal study under its open IND for SkinTE®.

PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update

SALT LAKE CITY , Nov. 9, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash. The offer is subject to various contingencies, including, among others, (1) settlement with warrant holders and satisfactory negotiations with insiders with change of control agreements, (2) minimum tender conditions, (3) a sixty-day due diligence period, and (4) satisfaction of other conditions and requirements that may arise, which are commonplace in transactions of this nature.

PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company

PolarityTE, Inc. (PTE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PolarityTE, Inc. (PTE) Upgraded to Strong Buy: Here's What You Should Know

SALT LAKE CITY , Sept. 13, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced it will present at the H.C.

PolarityTE to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022

SALT LAKE CITY , Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately.

PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors

PolarityTE, Inc. (NASDAQ:PTE ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Richard Hague - President & CEO Jacob Patterson - CFO Conference Call Participants Operator Good day, and welcome to the PolarityTE Second Quarter 2022 Business Update and Financial Results Conference Call. Today's conference is being recorded.

PolarityTE, Inc. (PTE) CEO Richard Hague on Q2 2022 Results - Earnings Call Transcript

PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET SALT LAKE CITY , Aug. 11, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended June 30, 2022.

PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update

SALT LAKE CITY , Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ: PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time.

PolarityTE to Report Q2 2022 Financial Results on August 11, 2022

SALT LAKE CITY , June 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the purchase and sale of 1,584,159 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $2.525 per share in a registered direct offering priced at-the-market under Nasdaq rules.  In a concurrent private placement, PolarityTE also agreed to issue and sell to the investor 1,584,159 shares of common stock (or pre-funded warrants in lieu thereof) at the same purchase price as in the registered direct offering.

PolarityTE Announces $8.0 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

SALT LAKE CITY , May 23, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that Richard Hague, Chief Executive Officer, and Nikolai Sopko, MD, PhD, Chief Scientific Officer, will present at the upcoming H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, in Miami and virtually.

PolarityTE to Attend H.C. Wainwright Global Investment Conference

A 1-for-25 reverse stock split of PolarityTE Inc (NASDAQ: PTE) has gone into effect. These are the details.

PolarityTE (PTE) Stock: 1-For-25 Reverse Split Goes Into Effect

SALT LAKE CITY , May 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that the Company will effectuate a 1-for-25 reverse stock split of the Company's issued and outstanding common stock, which will be effective under Delaware law at 4:15 p.m. Eastern Time on Monday, May 16, 2022.

PolarityTE to Effectuate 1-for-25 Reverse Stock Split

PolarityTE, Inc. (PTE) delivered earnings and revenue surprises of -25% and 12.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PolarityTE, Inc. (PTE) Reports Q1 Loss, Misses Revenue Estimates

PolarityTE, Inc. (NASDAQ:PTE ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Cameron Hoyler - General Counsel Richard Hague - Chief Executive Officer and President Jake Patterson - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Carl Byrnes - Northland Capital Markets Operator Good day, and welcome to the PolarityTE First Quarter 2022 Business Update Conference Call. Today's conference is being recorded.

PolarityTE, Inc. (PTE) CEO Richard Hague on Q1 2022 Results - Earnings Call Transcript

PolarityTE to host conference call and webcast today, May 16, 2022, at 8:30 a.m. ET SALT LAKE CITY , May 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the three-month period ended March 31, 2022.

PolarityTE Reports First Quarter 2022 Financial Results and Provides Business Update

PolarityTE (PTE) stock is rocketing higher on Friday thanks to positive news from the U.S. Food and Drug Administration (FDA). The post PTE Stock Soars 70% Following PolarityTE's New FDA Designation appeared first on InvestorPlace.

PTE Stock Soars 70% Following PolarityTE's New FDA Designation

SALT LAKE CITY , May 13, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) designation to SkinTE under the Company's open IND.  Established under the 21st Century Cures Act, RMAT designation is a dedicated program designed to expedite the drug development and review processes for promising regenerative medicine products, including human cellular and tissue-based therapies.

PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE®

SALT LAKE CITY , May 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the three-month period ended March 31, 2022, by press release on Monday, May 16, 2022, at approximately 7:30 a.m. Eastern Time.

PolarityTE to Report Q1 2021 Financial Results on May 16, 2022

Evoke Pharma

Globalstar

IT Tech Packaging Inc

Kala Pharmaceuticals

Kiromic Biopharma

MEI Pharma

Pingtan Marine Enterprise

Sesen Bio Inc.

Sonim Technologies Inc

Top penny stocks under $1 to watch in May. The post 10 Top Penny Stocks To Buy For Under $1 May 2022 Edition appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Buy For Under $1 May 2022 Edition

SALT LAKE CITY , May 3, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational use of treatment of Wagner grade 2 diabetic foot ulcers (DFUs), entitled "Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE," or "COVER DFUs."  COVER DFUs will enroll up to 100 subjects at up to 20 clinical sites in the United States.

PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

Lixte Biotech

RLX Technology

Check these three penny stocks out for your watchlist right now The post Penny Stocks to Buy For Your Watchlist Next Week  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks to Buy For Your Watchlist Next Week

Akebia Therapeutics

Brickell Biotech Inc

Borqs Technologies

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 5 Stocks Under $1 To Watch In April

PolarityTE has finally gained the traction that it deserves in the midst of an inflection point for the company. The post PTE Stock Is Rocketing Nearly 100% Today.

News for PolarityTE Inc Stock (PTE)